BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 30693099)

  • 1. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports.
    Tan MH; Iyengar R; Mizokami-Stout K; Yentz S; MacEachern MP; Shen LY; Redman B; Gianchandani R
    Clin Diabetes Endocrinol; 2019; 5():1. PubMed ID: 30693099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach.
    Yuen KCJ; Samson SL; Bancos I; Gosmanov AR; Jasim S; Fecher LA; Weber JS
    Endocr Pract; 2022 Jul; 28(7):719-731. PubMed ID: 35477029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrinopathies Associated With Immune Checkpoint Inhibitor Use.
    Kotwal A; Kennedy R; Kikani N; Thosani S; Goldner W; Shariff A
    Endocr Pract; 2024 Jun; 30(6):584-591. PubMed ID: 38554775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study.
    Bai X; Chen X; Wu X; Huang Y; Zhuang Y; Chen Y; Feng C; Lin X
    J Endocrinol Invest; 2020 Oct; 43(10):1473-1483. PubMed ID: 32239475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
    Bai X; Lin X; Zheng K; Chen X; Wu X; Huang Y; Zhuang Y
    Endocrine; 2020 Sep; 69(3):670-681. PubMed ID: 32507965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.
    Grouthier V; Lebrun-Vignes B; Moey M; Johnson DB; Moslehi JJ; Salem JE; Bachelot A
    Oncologist; 2020 Aug; 25(8):696-701. PubMed ID: 32390168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review.
    Stelmachowska-Banaś M; Czajka-Oraniec I
    Endocr Connect; 2020 Oct; 9(10):R207-R228. PubMed ID: 33064663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine immune-related adverse events: Adrenal, parathyroid, diabetes insipidus, and lipoatrophy.
    Atkinson M; Lansdown AJ
    Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101635. PubMed ID: 35382989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Uncharted Landscape of Rare Endocrine Immune-Related Adverse Events.
    Mytareli C; Ziogas DC; Karampela A; Papalexis P; Siampanopoulou V; Lafioniatis A; Benopoulou O; Gogas H; Angelousi A
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Endocrinopathies Associated with Immune Checkpoint Inhibitors].
    Santos MJ
    Acta Med Port; 2022 Mar; 35(3):209-215. PubMed ID: 35077347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolated adrenocorticotropic hormone deficiency following immune checkpoint inhibitors treatment often occurs in polyglandular endocrinopathies.
    Chen H; Zhang L; Zhao L; Li X
    BMC Endocr Disord; 2023 Jul; 23(1):139. PubMed ID: 37415148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The side effects of immune checkpoint inhibitor therapy on the endocrine system.
    Goyal I; Pandey MR; Sharma R; Chaudhuri A; Dandona P
    Indian J Med Res; 2021 Apr; 154(4):559-570. PubMed ID: 35435341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.
    Chang LS; Barroso-Sousa R; Tolaney SM; Hodi FS; Kaiser UB; Min L
    Endocr Rev; 2019 Feb; 40(1):17-65. PubMed ID: 30184160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors.
    Fujita Y; Kamitani F; Yamamoto M; Fukuoka H; Hirota Y; Nishiyama N; Goda N; Okada Y; Inaba Y; Nakajima H; Kurematsu Y; Kanie K; Shichi H; Urai S; Suzuki M; Yamamoto N; Bando H; Iguchi G; Suto H; Funakoshi Y; Kiyota N; Takahashi Y; Ogawa W
    J Endocr Soc; 2023 Jan; 7(3):bvad002. PubMed ID: 36694808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors.
    Iwama S; Kobayashi T; Arima H
    Endocrinol Metab (Seoul); 2021 Apr; 36(2):312-321. PubMed ID: 33934588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system.
    Yan YD; Zhao Y; Zhang C; Fu J; Su YJ; Cui XL; Ma EL; Liu BL; Gu ZC; Lin HW
    EClinicalMedicine; 2022 Aug; 50():101535. PubMed ID: 35812997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The changing clinical spectrum of endocrine adverse events in cancer immunotherapy.
    Chiloiro S; Bianchi A; Giampietro A; Milardi D; De Marinis L; Pontecorvi A
    Trends Endocrinol Metab; 2022 Feb; 33(2):87-104. PubMed ID: 34895977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. It's Not Always SIAD: Immunotherapy-Triggered Endocrinopathies Enter the Field of Cancer-Related Hyponatremia.
    Bischoff J; Fries C; Heer A; Hoffmann F; Meyer C; Landsberg J; Fenske WK
    J Endocr Soc; 2022 May; 6(5):bvac036. PubMed ID: 35356006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.